Date: 2014-10-29
Type of information: Nomination
Compound:
Company: Alnylam Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 29, 2014, Alnylam Pharmaceuticals, a leading RNAi therapeutics company, announced the appointment of Pushkal Garg , M.D., to the position of Senior Vice President, Clinical Development. Dr. Garg has extensive experience in clinical development across a broad range of therapeutic areas. At Alnylam, he will join the existing development team and be responsible for managing the company\'s clinical research, clinical operations, and biometrics functions. Dr. Garg joins Alnylam with close to 15 years of experience in clinical drug development. Most recently, he served as Vice President, Global Clinical Research , Immunoscience at BMS. In this role he was responsible for strategic leadership of the Immunoscience franchise and the successful development of multiple clinical assets across immune-mediated diseases in the areas of rheumatology, gastroenterology, nephrology, and transplantation. During his eight-year tenure at BMS, he was instrumental to the late-stage development and approval of Nulojix® (belatacept) for kidney transplant recipients, and for supplementary biologics license applications (BLA) for Orencia® (abatacept) around the world. Previously, Dr. Garg was at Millennium Pharmaceuticals , where he worked in various roles of increasing responsibility, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders. Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California , Berkeley , and an M.D. from the University of California , San Francisco . He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University , and served on the faculty of Harvard Medical School and the Brigham & Women\'s Hospital in Boston prior to joining industry.
Financial terms:
Latest news:
